timothy sykes logo

Stock News

Corcept Therapeutics Gains FDA Approval for Relacorilant in New Drug Application

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 10/4/2025, 9:17 am ET 10/4/2025, 9:17 am ET | 4 min 4 min read
Corcept Therapeutics Gains FDA Approval for Relacorilant in New Drug Application Thumbnail

Corcept Therapeutics Incorporated’s stocks have been trading up by 5.11 percent following recent positive sentiment from FDA designations and promising results.

Healthcare industry expert:

Analyst sentiment – positive

Corcept Therapeutics (CORT) is positioned robustly within the healthcare sector, driven by fundamentals that emphasize strong profitability and management effectiveness. The company boasts an EBIT margin of 17.6% and a pretax profit margin of 25.5%, indicative of efficient operational management. Furthermore, with a gross margin of 98.4%, Corcept demonstrates a commanding control over its production costs. Financially, Corcept’s balance sheet is solid, evidenced by a debt-to-equity ratio of 0.01, ensuring low leverage risk. Positive cash flow from operations fortifies its operational viability. However, a P/E ratio of 76.32 may suggest overvaluation relative to earnings, albeit consistent with industry dynamics.

On the technical front, Corcept’s price activity shows upward momentum, with the stock price moving from $83.9 on September 29 to $89.85 on October 3. The dominant trend is bullish, indicated by a sequence of higher highs and substantial trading volumes. The breakout above $85, which coincides with resistance turned support, is a key signal of continued upward movement. Traders should consider a strategy to ‘Buy on Dips’ near $85, with $90 as the next target level. Stop-loss orders could be placed at $83 to mitigate downside risk.

Catalysts strongly favor Corcept’s future, with notable developments around its relacorilant NDA. Meeting FDA acceptance fortifies its product pipeline, especially given the promising Phase 3 data. Media sentiment indicates significant bullishness, aligned with Canaccord’s raised price target to $140, reflecting structural growth potential. Comparatively, Corcept outpaces biotechnology benchmarks, attributed to its strategic drug development progress. Support is firm at $85, while the resistance at $90 could soon be challenged, fueled by positive trial outcomes. Corcept’s trajectory appears robust, warranting a positive outlook.

Candlestick Chart

Weekly Update Sep 29 – Oct 03, 2025: On Saturday, October 04, 2025 Corcept Therapeutics Incorporated stock [NASDAQ: CORT] is trending up by 5.11%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Recently released earnings reports underscore Corcept Therapeutics’ financial prowess. The highlight lies in its robust revenue stream of $675M indicating a promising horizon for the company. Key ratios, such as a notable EBIT margin of 17.6% and a commendable profit margin of 18.66%, amplify its sturdy operational efficiency. The company’s profitability and operational acumen are reinforced by an impressive gross margin of 98.4%. Additionally, the enterprise’s market valuation stands tall with an enterprise value of approximately $8.95B.

In terms of stock performance, recent data shows an upward trajectory with stock closing at $89.85 after starting at $88.15; this is mirrored in the positive news around FDA acceptance and improved forecasts. The Peratio at 76.32 is consistent with growth stocks in the biopharmaceutical industry, while a solid current ratio of 3.1 underpins its liquidity. With a long-term debt-to-equity ratio of virtually nil (0.01), Corcept is well-primed for strategic investments without the baggage of heavy financial liabilities.

Significant operational achievements such as those in last quarter’s report reflect increasing cash flows with over $43.9M and strengthening balance sheets with total assets around $801.72M. Consequently, current announcements hint at potential strategic avenues and locked capital for sustained growth and expansion.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”